Transforming growth factor b (TGFb) causes the acquisition of epithelialmesenchymal transition (EMT). Although the tumor suppressor gene PTEN (phosphatase and tensin homologue deleted from chromosome 10) can negatively regulate many signaling pathways activated by TGFb, hyperactivation of these signaling pathways is observed in lung cancer cells. We recently showed that PTEN might be subject to TGFb-induced phosphorylation of its C-terminus, resulting in a loss of its enzyme activities; PTEN with an unphosphorylated C-terminus (PTEN4A), but not PTEN wild, inhibits TGFb-induced EMT. Nevertheless, whether or not the blockade of TGFb-induced EMT by the PTEN phosphatase activity might be attributed to the unphosphorylated PTEN C-terminus itself has not been fully determined. Furthermore, the lipid phosphatase activity of PTEN is well characterized, whereas the protein phosphatase activity has not been determined. By using lung cancer cells carrying PTEN domain deletions or point mutants, we investigated the role of PTEN protein phosphatase activities on TGFb-induced EMT in lung cancer cells. The unphosphorylated PTEN C-terminus might not directly retain the phosphatase activities and repress TGFb-induced EMT; the modification that keeps the PTEN C-terminus not phosphorylated might enable PTEN to retain the phosphatase activity. PTEN4A with G129E mutation, which lacks lipid phosphatase activity but retains protein phosphatase activity, repressed TGFb-induced EMT. Furthermore, the protein phosphatase activity of PTEN4A depended on an essential association between the C2 and phosphatase domains. These data suggest that the protein phosphatase activity of PTEN with an unphosphorylated C-terminus might be a therapeutic target to negatively regulate TGFb-induced EMT in lung cancer cells.
Transforming growth factor b (TGFb) causes the acquisition of epithelialmesenchymal transition (EMT). Although the tumor suppressor gene PTEN (phosphatase and tensin homologue deleted from chromosome 10) can negatively regulate many signaling pathways activated by TGFb, hyperactivation of these signaling pathways is observed in lung cancer cells. We recently showed that PTEN might be subject to TGFb-induced phosphorylation of its C-terminus, resulting in a loss of its enzyme activities; PTEN with an unphosphorylated C-terminus (PTEN4A), but not PTEN wild, inhibits TGFb-induced EMT. Nevertheless, whether or not the blockade of TGFb-induced EMT by the PTEN phosphatase activity might be attributed to the unphosphorylated PTEN C-terminus itself has not been fully determined. Furthermore, the lipid phosphatase activity of PTEN is well characterized, whereas the protein phosphatase activity has not been determined. By using lung cancer cells carrying PTEN domain deletions or point mutants, we investigated the role of PTEN protein phosphatase activities on TGFb-induced EMT in lung cancer cells. The unphosphorylated PTEN C-terminus might not directly retain the phosphatase activities and repress TGFb-induced EMT; the modification that keeps the PTEN C-terminus not phosphorylated might enable PTEN to retain the phosphatase activity. PTEN4A with G129E mutation, which lacks lipid phosphatase activity but retains protein phosphatase activity, repressed TGFb-induced EMT. Furthermore, the protein phosphatase activity of PTEN4A depended on an essential association between the C2 and phosphatase domains. These data suggest that the protein phosphatase activity of PTEN with an unphosphorylated C-terminus might be a therapeutic target to negatively regulate TGFb-induced EMT in lung cancer cells.
L ung cancer remains a leading cause of cancer-related death worldwide. New therapeutic options available for lung cancer are likely to have a limited effect on improving survival rates in these patients, due to chemotherapy resistance and early cancer dissemination. (1) Mounting evidence suggests the importance of the tumor microenvironment in which cancer cells interact with fibroblasts and consequently acquire epithelial-mesenchymal transition (EMT). (2, 3) Persistent loss of epithelial markers and de novo expression of mesenchymal markers are involved during development of EMT. (4) Although transforming growth factor b (TGFb) is one of the most critical tissue-stiffening factors derived from tumor lesions, the recent studies showed that TGFb-induced transcription of EMT target genes such as fibronectin and vimentin is accelerated by translocation of b-catenin from E-cadherin complexes at the cell membrane into the cytoplasm. (5, 6) Although the tumor suppressor gene PTEN (phosphatase and tensin homologue deleted from chromosome 10) can negatively regulate many signaling pathways activated by TGFb, (7) hyperactivation of the signaling pathways induced by TGFb is often observed in lung cancer. (8) Loss of PTEN expression might accelerate the development of lung cancer in vivo. (9) Recent studies suggest that TGFb stimulation represses PTEN expression in epithelial cells in vitro. (6, 10) Meanwhile, phosphorylation of the PTEN C-terminus might induce a conformational change in PTEN structure that is closely associated with the loss of PTEN activity. (11, 12) The studies also indicated that the higher phosphorylation levels of the PTEN C-terminus in malignant leukemia cells were directly associated with loss of phosphatase activity and acquisition of aberrant cell phenotypes. (13, 14) We show that TGFb stimulation modifies phosphorylation of PTEN on its C-terminus (p-PTEN) in lung cancer cells, and consequently leads to the loss of PTEN activities; (6) unphosphorylated PTEN with four Ala substitutions of the phosphorylation sites in the PTEN C-terminus (PTEN4A) rescues cells from TGFb-induced loss of PTEN activities and the acquisition of EMT. (6) Nevertheless, whether or not the PTEN phosphatase activity might be attributed to the unphosphorylated PTEN C-terminus itself has not been fully determined. Although PTEN comprises the C-terminus and two other major domains, that is, the C2 and phosphatase domains, (15) several mutants of the PTEN phosphatase domain that modulate the PTEN phosphatase activities have been described. (7, (16) (17) (18) The lipid phosphatase activity of PTEN is well characterized, (19) whereas the PTEN protein phosphatase activity has not been fully determined. (18) In the present study, by using a Dox-dependent expression system to express a series of PTEN domain deletions and point mutants, we have investigated the enzyme's protein phosphatase activity, by which unphosphorylated PTEN might play a critical role in inhibiting TGFb-induced EMT and translocation of b-catenin in lung cancer cells.
Materials and Methods
Materials. Monoclonal mouse anti-PTEN antibody (clone 6H2.1) was from Cascade Bioscience (Winchester, UK). Purified rabbit anti-phospho-PTEN (Ser380 ⁄ Thr382 ⁄ Thr383) antibody, rabbit anti-pan-Akt antibody, rabbit anti-phospho-Akt (Thr308) antibody, rabbit anti-phospho-Akt (Ser473) antibody, rabbit anti-FAK antibody, and rabbit anti-phospho-FAK (Tyr397) antibody were from Cell Signaling Technology (Boston, MA, USA). Purified anti-fibronectin antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Purified and FITC mouse anti-E-cadherin antibody and anti-b-catenin antibody were from BD Biosciences (San Diego, CA, USA). Streptavidin (SAv)-Alexa 594 (SAv-594)-conjugated antimouse antibody was from Invitrogen Life Technologies (Carlsbad, CA, USA). Affinity-isolated rabbit anti-actin antibody was from Sigma-Aldrich (St. Louis, MO, USA). Can Get Signal was from Toyobo (Tokyo, Japan). Doxycycline, pTet-On Advanced, pTRE-Tight Vector, and Adeno-X Expression System 3 were from Clontech Laboratories (Mountain View, CA, USA). PhosSTOP was from Roche Applied Science (Mannheim, Germany). Hoechst33342 was from Dojindo (Kumamoto, Japan). 1,2,4,5-Benzenetetramine tetrahydrochloride (FAK inhibitor 14) was from Tocris Bioscience (Bristol, UK).
Plasmids and gene transfection. The Dox-dependent gene expression system was applied to H358 cells, a human lung cancer cell line, carrying pTet-On Advanced (H358ON). (6) H358ON cells express GFP in the pTRE-Tight vector (GFP), or GFP fused to PTEN with four Ala substitutions (S380A, T382A, T383A, and S385A) on the C-terminus (PTEN4A) through the pTRE-Tight Vector (GP4A). (6) All of the PTEN domain-deletion mutants used in this study were prepared from GP4A. (15) Furthermore, by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), the following functionally selective mutants of the PTEN phosphatase domain were also established: (i) PTEN C124S, in which Cys124 is replaced with Ser, which lacks both lipid and protein phosphatase activities; (17) (ii) PTEN G129E, in which Glu replaces Gly129, which lacks lipid phosphatase activity but retains protein phosphatase activity; (16, 17) and (iii) PTEN Y138C, in which Tyr138 is substituted with Cys, which selectively retains lipid phosphatase activity but lacks substantial protein phosphatase activity. (7, 18) Adenovirus carrying the GFP-PTEN4A C2 domain only (adeno G4A C2 only) was also established from the GFP-PTEN4A C2 domain only in the pTRE-Tight Vector, by using the Adeno-X Expression System 3 (Clontech) in accordance with the manufacturer's instruction. We defined one MOI as a total of 1 9 10 6 pfu of adeno G4A C2 only per 1 9 10 6 cells per a plate. Cells. H358ON cells was maintained in RPMI supplemented with 2 mmol ⁄ L L-glutamine, Antibiotic-Antimycotic (Thermo Fisher Scientific, Inc., Waltham, MA), and 10% FCS. (20) To evaluate the effect of TGFb, the cells were treated with TGFb at 2 ng ⁄ mL and analyzed for mRNA levels and protein levels at the indicated time points (see below). To evaluate the effect of PTEN transduction on TGFb stimulation, H358ON cells expressing Dox-dependent PTEN constructs were incubated with 1 lg ⁄ mL Dox at for 24 h at 37°C before TGFb treatment. (6) In the adeno reconstitution model, H358ON cells expressing Dox-dependent G4A G129E lacking the PTEN C2 domain (G4A G129E D C2) were pretreated with 10 MOI of adeno G4A C2 only 24 h before Dox treatment.
Western blot analysis. For whole-cell extracts, cells were harvested in ice-cold lysis buffer and cleared by centrifugation. (21, 22) The samples were then subjected to SDS-PAGE and analyzed by immunoblotting. To detect phosphorylation levels of the targeted proteins, Phosphostop was added to the lysis buffer and Can Get Signal was added to the dilution solution for primary and secondary antibodies. b-actin was evaluated as a loading control.
Immunofluorescence and confocal laser scanning microscopy. Immunocytochemistry was carried out as previously described. (6, 23) To evaluate the effect of PTEN4A or PTEN mutants on the TGFb-induced translocation of b-catenin, H358ON cells expressing Dox-dependent PTEN mutants were incubated with anti-b-catenin antibody, followed by SAv-594-conjugated anti-mouse antibody. Nuclear staining was carried out using Hoechst 33342. The distribution of b-catenin was determined by confocal laser scanning microscopy (LSM 5 PASCAL; Carl Zeiss, Jena, Germany). The fluorescence intensities of b-catenin and the nucleus were evaluated by using imaging software (LSM Software ZEN 2008; Carl Zeiss), which plotted fluorescence intensities over a random cross-section of the cells. (24, 25) The subcellular distribution of PTEN was determined by confocal laser scanning microscopy. A minimum of five randomly selected high-power fields were examined per sample to measure fluorescence intensity in the nucleus and the cytoplasm. (26) To determine localization of b-catenin in the cell membrane, double immunostaining was carried out for b-catenin and E-cadherin in the cells. (27) Statistical analysis. The results were analyzed using the Mann-Whitney U-test for comparison between any two groups, and by non-parametric equivalents of ANOVA or multiple comparisons. A value of P < 0.05was considered to indicate statistical significance.
Results

Unphosphorylated PTEN C-terminus might not directly inhibit
TGFb-induced EMT in H358 cells. To determine whether the PTEN C-terminus with four Ala substitutions might directly modulate the acquisition of TGFb-induced EMT, we established H358ON cells Dox-dependently expressing either GFP-PTEN4A with deletion of the tail (G4A D tail) or GFP-PTEN4A tail only (G4A tail only), which lacks both C2 and phosphatase domains (Fig. 1a) . First, the expression of these mutants was verified by Western blotting of cells grown in the absence or presence of Dox. Although G4A tail expression induced by Dox was detected by an anti-PTEN antibody that recognizes the PTEN C-terminus, expression of G4A D tail expression was not detected (Fig. 1b,c) . In contrast, Western blotting with anti-GFP antibody showed the expression of GFP-tagged proteins with the sizes expected for the G4A D tail and G4A tail, respectively (Fig. 1b,c) . Next, we evaluated the effect of G4A D tail and G4A tail on TGFb-induced signaling pathways. We recently showed that TGFb-induced phosphorylation of Akt at Thr308 and Ser473 (Akt308 and Akt473) and FAK was repressed in H358 ON cells with G4A (Fig. S1a,b) . (6) We evaluated the effects of G4A tail protein and GFP4A D tail protein on these phosphorylation signals ( Fig. 1d-g, S1c,d ). De novo expression of G4A tail protein did not inhibit TGFb-induced phosphorylation of Akt308, Akt473, or FAK (Figs 1e,g, S1d). In contrast, these phosphorylation signals were inhibited by de novo GFP4A D tail protein in H358ON cells (Figs 1d,f, S1c). To evaluate the effect of the PTEN mutants on TGFb-induced EMT, Western blotting analysis for fibronectin (5, 28) and E-cadherin (5, 29) was carried out after treatment with vehicle or TGFb for 48 h in the absence or presence of Dox. A previous study showed that compensatory induction of PTEN4A repressed TGFb-induced EMT through complete blockade of b-catenin translocation to the cytoplasm and the nucleus. (6) Furthermore, double immunostaining showed colocalization of b-catenin and E-cadherin on the cell membrane in the cells (Fig. S1e) . There was no reduction in the increasing fibronectin ⁄ E-cadherin ratio (F ⁄ E ratio) in TGFb-treated cells expressing G4A tail (Fig. 1j) ; however, expression of G4A D tail yielded a significant decrease in the F ⁄ E ratio (Fig. 1i) , similar to those in H358ON cells with G4A (Fig. 1h) . Localization of b-catenin was evaluated in TGFb-treated H358ON cells expressing Dox-dependent G4A tail and G4A D tail protein by immunofluorescence coupled with confocal microscopy. b-catenin appeared localized on the cell membrane in H358ON cells expressing Doxdependent G4A tail or G4A D tail when no TGFb was added (Fig. 1m-p) . Translocation of b-catenin into the cytoplasm and the nucleus was observed after TGFb stimulation in H358ON cells expressing G4A tail protein (Fig. 1o,p) . In contrast, bcatenin was completely retained on the cell membrane in H358ON cells after TGFb stimulation in H358ON cells expressing de novo GFP4A D tail protein (Fig. 1m,n) , similar to those in H358ON cells with G4A (Fig. 1k,l) . Furthermore, TGFb-induced EMT and b-catenin translocation into the cytoplasm and the nucleus was also not blocked in H358ON cells expressing GFP-PTEN wild tail only (Fig. S2a-d S2e-h ). Taken together, these data suggested that the unphosphorylated PTEN C-terminus itself might not directly retain the phosphatase activities and repress TGFb-induced EMT; the modification that keeps the PTEN C-terminus not phosphorylated might enable PTEN to retain the phosphatase activity and inhibit TGFb-induced EMT.
Both C2 and phosphatase domains of unphosphorylated PTEN might be essential for inhibiting TGFb-induced EMT in H358 cells.
To determine the biological roles of the C2 and phosphatase domains of PTEN4A in the inhibition of TGFb-induced EMT, we established H358ON cells expressing Dox-dependent GFP-PTEN4A lacking the phosphatase domain (G4A D phosphatase), GFP-PTEN4A lacking the C2 domain (G4A D C2), and GFP-PTEN4A containing the C2 domain only (G4A C2 only) (Fig. 2a) . The expression of these mutants was verified by Western blotting of cells grown in the absence or presence of Dox. Western blotting with anti-GFP antibody showed the expression of GFP-tagged proteins of the expected size of G4A D phosphatase, G4A D C2, and G4A C2 only, in Doxtreated cells (Fig. 2b-d) . First, we evaluated PTEN phosphatase activities in cells expressing these mutants. Whereas Dox-treated H358ON cells expressing PTEN4A or G4A D tail showed repression of TGFb-induced FAK and Akt activation through PTEN phosphatase activities (Fig. 1d,f and data not shown), expression of G4A D phosphatase, G4A D C2, or G4A C2 only did not appear to inhibit TGFb-induced FAK and Akt activation in H358On cells (Fig. 2e-j) , indicating that the phosphatase activities in PTEN4A might be orchestrated by both the C2 and the phosphatase domains. Western blot analysis for EMT markers showed that there was no reduction in the increasing F ⁄ E ratio in TGFb-treated cells expressing G4A D phosphatase, G4A D C2, or G4A C2 only (Fig. 3a-c) ; thus, these mutants had no effect on TGFb-induced EMT. To elucidate the underlying mechanism, immunofluorescence was carried out in cells expressing these deletion mutants. Treatment with TGFb induced b-catenin translocation from the cell membrane to the cytoplasm and the nucleus in H358ON cells expressing each of the mutants (Fig. 3d-i) . Taken together, these results indicate that the close association of both the C2 and phosphatase domains might be essential to inhibit the acquisition of TGFb-induced EMT and to block the underlying mechanisms in lung cancer cells. satory expression of PTENWild (PTENWt) inhibits TGFbinduced PI3K ⁄ Akt signaling in lung cancer cells, whereas it only partially inhibits TGFb-induced EMT.
(6) Therefore, we hypothesized that the protein phosphatase activity of PTEN might be involved in the inhibition of TGFb-induced EMT caused by PTEN4A in H358ON cells. To evaluate the role of PTEN phosphatase activity, therefore, we established H358ON cells expressing Dox-dependent GFP-PTEN4A with C124S (G4A C124S), GFP-PTEN4A with G129E (G4A G129E), and GFP-PTEN4A with Y138C (G4A Y138C) (Fig. 4a-d) , three point mutants that show distinct characteristics of phosphatase activity. First, we determined whether TGFb-induced FAK and Akt activation could be modulated by these point mutants. De novo G4A C124S expression did not inhibit TGFb-induced FAK and Akt activation (Fig. 4e-h ), indicating that H358ON cells expressing G4A C124S retain neither the lipid phosphatase activity nor the protein phosphatase activity of PTEN. De novo G4A G129E expression inhibited TGFb-induced FAK activation, but not Akt activation (Fig. 4f,i) , indicating that H358ON cells expressing G4A G129E retain the protein phosphatase activity but lack the lipid activity of PTEN. In contrast, de novo G4A Y138C expression inhibited TGFb-induced Akt activation, but not FAK activation (Fig. 4g,j) , indicating that H358ON cells expressing G4A Y138C retain the lipid phosphatase but lack the protein phosphatase activity of PTEN. Next, we used H358ON cells expressing these mutants to evaluate the effect of PTEN phosphatase activities on EMT. There was no reduction in the increasing F ⁄ E ratio in TGFb-treated cells expressing G4A C124S even when Dox was added (Fig. 5a ). In addition, expression of G4A G129E repressed the TGFb-induced EMT phenotype (Fig. 5b) , whereas de novo expression of G4A Y138C did not inhibit TGFb-induced acquisition of the EMT phenotype (Fig. 5c) . Furthermore, localization of b-catenin was evaluated in these cells (Fig 5d-i) . Although TGFb-induced translocation of b-catenin from the cell membrane to the cytoplasm and the nucleus was not blocked in H358ON cells expressing Dox-dependent G4A C124S or G4A Y138C (Fig. 5d ,e,h,i), de novo expression of G4A G129E completely retained localization of b-catenin on the cell membrane (Fig. 5f,g ). These findings indicate that the protein phosphatase activity of PTEN, but not the lipid phosphatase activity, might be involved in inhibiting TGFb-induced EMT and in blocking the associated b-catenin translocation.
C2 domain might be essential for protein phosphatase activity of unphosphorylated PTEN in H358 cells. To determine whether the association of both the C2 and phosphatase domains might be essential for PTEN4A to show protein phosphatase activity, we established H358ON cells expressing G4A G129E lacking the PTEN C2 domain (G4A G129E D C2) (Fig. 6a) . Western blotting verified that the cells expressed protein of the expected sized (Fig. 6b) . De novo expression of G4A G129E D C2 did not inhibit TGFb-induced FAK activation (Fig. 6c) , indicating the close association of both the C2 and phosphatase domains might be essential for the protein phosphatase activity of PTEN4A. In TGFb-treated cells expressing the G4A G129E D C2 domain, there was no reduction in the increasing F ⁄ E ratio (Fig. 6d) and translocation of b-catenin from the cell membrane into the cytoplasm and the nucleus (Fig. 6e,f) was observed. Finally, to determine whether the PTEN C2 domain is essential for the inhibition of TGFb-induced EMT by protein phosphatase activity, a model of PTEN C2 domain reconstitution was established in H358ON cells expressing Dox-dependent G4A G129E D C2 using adeno G4A C2 only (Fig. 6g,h ). Recon- stitution of the PTEN C2 domain by adeno G4A C2 only led to the inhibition of both TGFb-induced FAK activation in H358ON cells expressing G4A G129E D C2 (Fig. 6i) , TGFb-induced EMT (Fig. 6j) , in addition to blockade of bcatenin translocation from the cell membrane into the cytoplasm and nucleus (Fig. 6k,l) . Taken together, these data suggest that compensatory induction of PTEN4A might negatively regulate TGFb-induced EMT and the associated translocation of b-catenin through its protein phosphatase activity, for which the C2 and the phosphatase domains might both be essential.
Discussion
There is an increasing awareness of the tumor microenvironment, in which intercellular communication between cancer- associated fibroblasts (30, 31) and cancer cells might influence the behavior of lung cancer cells. (2) Aberrant activation of the inducers of EMT, such as TGFb stimulation and persistent hypoxia, is often observed in tumor microenvironment; as a consequence, lung cancer cells acquire the malignant phenotypes. (20, 32, 33) Therefore, prevention of the EMT process, in which excessive ECM production and loss of alveolar epithelial cell integrity are involved, (4) is one of the most critical approaches for treating lung cancer cells. (34) Although intercellular transfer of the newly proposed PTEN variants such as alternative transcriptional PTEN (PTEN-Long) and monoubiquitinated PTEN (exosomal PTEN) (35, 36) might be proposed as a biopharmaceutical approach to treat lung cancer cells that lose functional PTEN, (9) intercellular transfer of PTENWt into cancer cells in the tumor microenvironment might not be enough to exert a therapeutic effect because PTENWt remains subject to TGFb-induced phosphorylation of its C-terminus, resulting in a loss of its enzyme activities. (6, 37, 38) Furthermore, to successfully achieve exogenous transfer of the targeted molecule, research on therapeutically important proteins has focused on miniaturization of protein-specific functions because of size constraints in exogenous administration. (39) The PTEN C-terminus with four Ala substitutions cannot be phosphorylated on its C-terminus, even after TGFb stimulation. (6) Indeed, our data suggest that compensatory induction of PTEN4A successfully represses the TGFb-induced acquisition of EMT in lung cancer cells, whereas de novo PTENWt expression shows limited repression of TGFb-induced EMT, probably due to TGFb-induced phosphorylation of its C-terminus. (6) Nevertheless, whether or not the unphosphorylated PTEN C-terminus itself might directly modulate the TGFbinduced acquisition of EMT in lung cancer cells has not been fully determined. The present data showed that the PTEN Cterminus itself (G4A tail) might not be involved in the lipid and protein phosphatase activities of PTEN, as evaluated by the levels of TGFb-induced Akt and FAK phosphorylation, respectively. Furthermore, the PTEN C-terminus did not appear to directly modulate TGFb-induced EMT in lung cancer cells, or to inhibit translocation of b-catenin from the cell membrane into the cytoplasm and the nucleus in cells treated with TGFb. Meanwhile, PTEN lacking the C-terminus but including the catalytic core of the C2 and phosphatase domains (G4A D tail) repressed TGFb-induced phosphorylation of FAK and Akt to basal levels through PTEN phosphatase activities, consistent with previous data. (40, 41) The cells expressing G4A D tail did not undergo TGFb-induced EMT, and b-catenin remained localized on the cell membrane in cells treated with TGFb, compatible with the cell expressing PTEN4A (GP4A). The unphosphorylated PTEN C-terminus might be critical for stable intramolecular interactions between the C2 and phosphatase domains of PTEN. (40, 42) Taken together, these data suggested that the approach that keeps the PTEN C-terminus not phosphorylated might be crucial for the unphosphorylated PTEN to inhibit TGFb-induced EMT.
Although the C2 and phosphatase domains, that is, the minimal catalytic core of PTEN, are required to interact with the plasma membrane to inhibit Akt activity through the lipid phosphatase activity, (18, 40) whether or not the close association between the C2 and phosphatase domains might be essential to exert protein phosphatase activity and negatively regulate TGFb-induced EMT in lung cancer cells remains unclear. To determine the contribution of the C2 and phosphatase domains, we evaluated the effect of several PTEN domain deletion mutants in TGFb-stimulated lung cancer cells. Although PTEN4A negatively regulates TGFb-induced Akt and FAK phosphorylation, we considered that a PTEN mutant lacking either the phosphatase domain (G4A D phosphatase) or the C2 domain (G4A D C2) might lose both its lipid and protein phosphatase activities. Compensatory induction of G4A D phosphatase could not retain the protein activity and blunt TGFbinduced EMT. These findings strengthened the hypothesis that the phosphatase domain involves the essential regions required to exert protein phosphatase activity. (7, (16) (17) (18) Meanwhile, when G4A D C2, in which the phosphatase domain is involved, was induced, protein phosphatase activity could not be restored and TGFb-induced EMT remained persistent. PTEN lacking the C2 domain or the phosphatase domain could not inhibit TGFbinduced translocation of b-catenin from the cell membrane into the cytoplasm and the nucleus. A previous study indicates that PTEN lipid phosphatase activity might involve the association of both the C2 and phosphatase domains. (40) Taken together, these data indicate that both the C2 and phosphatase domains might be essential to exert phosphatase activity and negatively regulate TGFb-induced EMT.
Previous studies have shown that both LY294002, a PI3K ⁄ Akt inhibitor, and rapamycin, an mTOR-specific inhibitor do not rescue EMT. (43, 44) To determine which of the PTEN phosphatase activities, that is, lipid or protein phosphatase activity, might negatively control TGFb-induced EMT in lung cancer cells, we established lung cancer cells expressing previously characterized PTEN mutants with different alterations in phosphatase activities. (7, (16) (17) (18) De novo expression of the unphosphorylated PTEN mutants without protein phosphatase activity (C124S and Y138C) did not repress TGFb-induced EMT in lung cancer cells, whereas unphosphorylated PTEN with protein phosphatase activity (G129E) did repress TGFb-induced EMT; (41) in addition, de novo expression of G129E, but not C124S or Y138C, inhibited TGFb-induced b-catenin translocation from the cell membrane into the cytoplasm and nucleus. Together, our data suggest a new role of PTEN protein phosphatase activity to negatively regulate the acquisition of TGFb-induced EMT in lung cancer cells.
Although the close association of both the PTEN C2 and phosphatase domains might be essential for unphosphorylated PTEN to block TGFb-induced EMT, whether or not the close association of both the PTEN C2 and phosphatase domains might be essential for PTEN protein phosphatase activity remains elusive. Therefore, we reconstituted PTEN in cells expressing G4A G129E D C2 by adeno GP4A C2 only. De novo G4A G129E D C2 showed no PTEN protein phosphatase activity in lung cancer cells stimulated by TGFb, and abrogated the inhibition of TGFb-induced EMT in lung cancer cells. Subsequently, reconstitution of the PTEN C2 domain in these cells by adeno GP4A C2 only restored PTEN protein phosphatase activity and its associated inhibition of TGFbinduced EMT. Thus, although the protein phosphatase activity of PTEN has not been fully characterized, (18) we have shown for the first time that a critical association between the C2 and phosphatase domains might be essential for unphosphorylated PTEN to retain its protein phosphatase activity and to inhibit TGFb-induced EMT in lung cancer cells. Although a recent study suggests that TGFb-induced transcription of EMT target genes such as fibronectin and vimentin is accelerated by translocation of b-catenin from E-cadherin complexes at the cell membrane into the cytoplasm, (5) the exact mechanism by which PTEN with an unphosphorylated C-terminus might block TGFb-induced b-catenin translocation from the cell membrane into the cytoplasm, remains elusive. Nevertheless, our data indicate that PTEN protein phosphatase activity might be closely associated with inhibiting the translocation of bcatenin from the cell membrane, possibly through the blockade of b-catenin phosphorylation. (45) (46) (47) In summary, we demonstrated that PTEN with an unphosphorylated C-terminus exerted its functions through its protein phosphatase activity, which in turn might depend on an essential association between the C2 and phosphatase domains. PTEN4A might negatively regulate TGFb-induced EMT and the associated translocation of b-catenin through its protein phosphatase activity. These data suggest that the protein phosphatase activity of PTEN with an unphosphorylated C-terminus might be a therapeutic target to negatively regulate TGFbinduced EMT during development of lung cancers.
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